Table 2.
Mean annual consumption of healthcare resources of the ≥ 3rd L cohort, by type of TKI
| Bosutinib (n = 24) | Dasatinib (n = 23) | Imatinib (n = 38) | Nilotinib (n = 27) | Ponatinib (n = 32) | |
|---|---|---|---|---|---|
| Drugs TKI excluded | 10.7 (6.4) | 9.0 (6.5) | 10.5 (7.8) | 7.9 (7.0) | 9.8 (5.9) |
| Visits | 7.4 (6.7) | 8.0 (7.7) | 5.1 (4.9) | 4.5 (3.5) | 8.4 (6.5) |
| Specific blood tests | 35.2 (30.9) | 27.5 (23.9) | 15.9 (16.5) | 23.3 (19.3) | 46.3 (41.4) |
| Other diagnostic/imaging tests | 60.4 (51.9) | 66.2 (49.8) | 60.4 (78.0) | 49.9 (36.3) | 91.5 (90.2) |
| BCR tests | 1.5 (2.3) | 1.3 (1.8) | 1.7 (1.8) | 2.1 (2.4) | 2.1 (2.4) |
| Hospitalizations | 0.5 (0.9) | 0.5 (1.0) | 0.4 (1.2) | 0.4 (0.7) | 0.7 (1.2) |
Data are presented as mean number (SD)